panitumumab
amgen,takeda
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm']
paradigm will not be the final answer for ras wild-type crc: there is a clear violation of non-proportional hazards premise, and survival estimates based either on km or cox regression do not hold.#asco2022 #paradigm 
M.D., Sc.D., oncologist, champion of universal access to cancer prev & treat. Opinion my own, RT = support/endorsement.